AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication - Wikidata - wikimedia - TriplyDB

AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication

AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication

http://www.wikidata.org/entity/Q35168444

about

Genome-editing Technologies for Gene and Cell Therapy Progress and Prospects of Anti-HBV Gene Therapy Development Roles of hepatocyte nuclear factors in hepatitis B virus infection Current and future antiviral drug therapies of hepatitis B chronic infection Therapeutic genome editing: prospects and challenges Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment In vivo dynamics of AAV-mediated gene delivery to sensory neurons of the trigeminal ganglia Long-Term Assessment of AAV-Mediated Zinc Finger Nuclease Expression in the Mouse Brain.CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus Genome editing and the next generation of antiviral therapy.In vivo disruption of latent HSV by designer endonuclease therapy Targeting Hepatitis B Virus With CRISPR/Cas9.Present and future therapies of hepatitis B: From discovery to cure Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy.Digital detection of endonuclease mediated gene disruption in the HIV provirus.Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications.Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.Gene therapeutic approaches to inhibit hepatitis B virus replication.Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.Advances in therapeutics for chronic hepatitis B.The state of gene therapy research in Africa, its significance and implications for the future.Viral life cycle of hepatitis B virus: Host factors and druggable targets.Eradication Strategies for Chronic Hepatitis B Infection.Review article: novel therapies for hepatitis B virus cure - advances and perspectives.Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities Virus-host interplay in hepatitis B virus infection and epigenetic treatment strategies.Tuning DNA binding affinity and cleavage specificity of an engineered gene-targeting nuclease via surface display, flow cytometry and cellular analyses.New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection.CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.Quantification of designer nuclease induced mutation rates: a direct comparison of different methods.Pharmacodynamics of anti-HIV gene therapy using viral vectors and targeted endonucleases.Combining Engineered Nucleases with Adeno-associated Viral Vectors for Therapeutic Gene Editing.Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?Genome editing technologies to fight infectious diseases.Advanced Strategies for Eliminating the cccDNA of HBV.Ex vivo and in vivo genome editing: a regulatory scientific framework from early development to clinical implementation.CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile?Gene Therapy for Chronic HBV-Can We Eliminate cccDNA?Drugs in Development for Hepatitis B.

P2860

Q26769662-25B69D25-6A3A-480E-92B3-ABAA0EE6D132 Q26799228-E43E78E4-E3A6-452B-BAFE-0311F1B47634 Q28069574-2B216A45-8C8E-4A16-BF9F-3E81DE352110 Q28084820-1557B34F-9535-42DA-A0DE-B90C53176A76 Q28087380-087703A2-B0F7-459F-AD5D-368419A72D93 Q28087526-37DC45D0-8C5D-46DC-AC98-2DAE092C7B82 Q33680976-E3D2DD74-176E-40E1-BE6D-B05FD5743BC0 Q33715367-6B561FEA-0F12-430F-A19F-B48AAC811D7F Q34478938-FB09FA0A-8D78-4E50-9E30-A4EBF422E601 Q34529971-FB274946-DE79-4F3F-886F-155FA87AF963 Q34540648-17C123F0-A87A-4C75-AC27-8C29FFB0E8DD Q34745348-02E9CBAC-DF4B-4CB0-9B56-AE2830CBDC4B Q36378278-8AD19CC1-6590-43D9-9722-4248EACA2CF2 Q36494284-CB074E06-2C9C-434E-894C-B1A55C67896C Q36528328-7CF4D9BA-ED66-4523-85A4-14939B34F7F2 Q36675277-829E5121-EA6A-454E-A4D3-95585944D736 Q36951290-461A3AB7-7C09-4062-A4BA-AC2EFA804F10 Q38351585-BEBC94BA-8BF3-4A67-9B39-E5ECD160D95F Q38366585-3C1563CB-B7F3-4295-9877-769FC6777559 Q38566445-7A71FFF7-CAD7-4414-8B1A-F3FE76E281DF Q38585657-1FF28C08-8E91-45DA-87B8-3BEE9750C2C0 Q38660339-EC9D39A1-86B3-4345-AADB-DB451D18876B Q38699649-C3574EC6-FB85-43BB-8FB0-72C51703D8F6 Q38837065-F7804B4D-E308-488D-97DC-249096258864 Q38865511-42D66D55-4584-45A3-9EC0-1822A9214BF6 Q38980907-28ECE184-52EF-4BF0-A357-EC61A2F3AE93 Q39272853-96E035FA-3C98-43A5-ACD5-D0B81F879C84 Q40057209-93A0A440-72BF-4F13-AD0D-8A8559ADBDF1 Q40130098-C378A3CC-CF71-456E-93C7-250067133170 Q40580426-1EE03258-0564-4C5C-A433-23AD0742103E Q40649902-F9213C5B-0134-4AE6-8407-046B7BB58576 Q40709550-079D7A4D-45AA-4150-8DDE-C6BE26228AA3 Q45874360-1077B8AF-6654-4F23-90EA-FC57ADE432C5 Q47136128-29B7AEF6-DAD7-4D93-9F5F-4455CA933782 Q47392998-00CA6C63-02DF-4CE8-8126-2223340700B8 Q47574790-4F822FAB-894D-4132-99C3-4FF5D0D05ADF Q48529117-48ED4C11-C7B2-4D0B-B22F-3FA3080A9EDC Q52430698-2CA015C0-A9B8-41D8-BB3F-60719DC29BF0 Q52431500-A5DB15C7-7F14-406E-A020-9598B4F58DFF Q52764230-09DF1125-33CE-4840-824F-3E8BA5F4DD59

P2860

AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication

http://www.wikidata.org/entity/Q35168444

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

AAV-mediated delivery of zinc ...... us inhibits active replication

@ast

AAV-mediated delivery of zinc ...... us inhibits active replication

@en

type

label

AAV-mediated delivery of zinc ...... us inhibits active replication

@ast

AAV-mediated delivery of zinc ...... us inhibits active replication

@en

prefLabel

AAV-mediated delivery of zinc ...... us inhibits active replication

@ast

AAV-mediated delivery of zinc ...... us inhibits active replication

@en

P1433

Q35168444-A39126EB-6C76-4F3F-91CC-97702EF48721

P1476

Q35168444-EB277CF2-EC34-4B4B-A641-0DEB08762FB4

P2093

Q35168444-04F8DFDE-1589-42E5-83B6-17AEFFFBB652

Q35168444-1DDB70CF-C67D-4007-9846-24373FB7792D

Q35168444-4264C104-39BA-423E-B98C-B00A608E2B26

Q35168444-A46B7AE6-64E1-4F95-957E-905E5DDB035F

Q35168444-ABB3941A-1B9B-4637-AD6A-64D79A90A95D

Q35168444-DEFB46AF-2E29-40E8-A1DE-A870CBECF27E

P2860

Q35168444-070A8571-B75C-4DF3-8D5D-9D2126C66B54

Q35168444-0E40911A-B2AC-4361-B16A-9797FA2A2ECF

Q35168444-0FB4CA6D-3578-4ABF-8CC8-FA1AFDAB6CB7

Q35168444-116AF15C-4D22-43E6-8623-01C434CF8548

Q35168444-199E2780-144D-45E3-8175-A72D5F38F02A

Q35168444-1FA2DDA4-C571-48A1-84B2-FE40F7FBB56F

Q35168444-1FB2541A-45D5-4F7E-A5CC-7F47C1CCCCC7

Q35168444-21755979-CC39-477A-BF3C-B3EA9179D67C

Q35168444-218B9B18-1048-4AE7-BFF4-497A761E2B4D

Q35168444-28001131-22D2-44DC-921A-8B01C78DA2CE

P304

Q35168444-B3E986C1-168D-41DE-97AF-EFCC774AE476

P31

Q35168444-DEEA3B61-2114-4ACC-862B-AC62E38ED7FB

P356

Q35168444-D65957C0-B1ED-4024-BD61-C1A89AC2F663

P407

Q35168444-B66F2318-95D4-4E05-9999-3EDA2B313057

P433

Q35168444-35288E43-F7A7-40DF-8E79-220AF6DEE1C7

P478

Q35168444-02FDA9A8-A487-4006-8F24-7180F02AEF65

P50

Q35168444-21B610EC-2B6D-47E4-8A3E-D857B6A4832B

Q35168444-948FB239-63FC-4753-A7E6-91BA5BB37C33

P577

Q35168444-635AD504-470E-41A8-9F99-725FA70EA09F

P5875

Q35168444-2994A69F-E337-42FD-A2AD-50D9B19D8D0C

P698

Q35168444-FD393A3E-3A6D-4B78-95A3-DF9219B46900

P932

Q35168444-F393C3BC-3E0C-4B39-9C98-269F8E45507D

P356

JOURNAL.PONE.0097579

P1433

P1476

AAV-mediated delivery of zinc ...... us inhibits active replication

@en

P2093

Harshana S De Silva Feelixge

http://www.w3.org/2001/XMLSchema#string

Joshua T Schiffer

http://www.w3.org/2001/XMLSchema#string

Keith R Jerome

http://www.w3.org/2001/XMLSchema#string

Martine Aubert

http://www.w3.org/2001/XMLSchema#string

Nicholas D Weber

http://www.w3.org/2001/XMLSchema#string

Ruth Hall Sedlak

http://www.w3.org/2001/XMLSchema#string

P2860

The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variants

Targeted DNA mutagenesis for the cure of chronic viral infections

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model

Multiple sequence alignment with the Clustal series of programs

Targeted gene disruption to cure HIV

Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach

Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis

In vivo genome editing restores haemostasis in a mouse model of haemophilia

Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection

An improved zinc-finger nuclease architecture for highly specific genome editing

P304

e97579

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0097579

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Pavitra Roychoudhury

P577

2014-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262338774

http://www.w3.org/2001/XMLSchema#string

P698

24827459

http://www.w3.org/2001/XMLSchema#string

P932

4020843

http://www.w3.org/2001/XMLSchema#string